Skip to content
Deepak Madhao Sahasrabudhe, M.D.

Deepak Madhao Sahasrabudhe, M.D.

Cancer

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

About Me

There are general principles of cancer care that have withstood the test of time. However, scientific and technologic advances are being made rapidly. As an oncologist, I always remember that a patient is at the end of every stethoscope, robot, sequencing machine and so on.

I chose this field...
There are general principles of cancer care that have withstood the test of time. However, scientific and technologic advances are being made rapidly. As an oncologist, I always remember that a patient is at the end of every stethoscope, robot, sequencing machine and so on.

I chose this field because it is most interdisciplinary and dynamic – plus, I work with a team of outstanding colleagues. I have a special interest in what was once called tumor immunology, now referred to as immuno-oncology.

Conditions I Treat

- Melanoma
- Prostate cancer
- Urinary cancer
- Bladder cancer
- Kidney cancer
- Testicular cancer
- Penile cancer
- Rare cancers such as Merkel cell carcinoma and Kaposi's sarcoma

Professional Background

Deepak Sahasrabudhe is a Professor of Medicine in the Division of Hematology/Oncology at the James P. Wilmot Cancer Center at the University of Rochester School of Medicine and Dentistry in Rochester, New York. Dr. Sahasrabudhe received his training at Albany Medical Center Hospital in Albany, New ...
Deepak Sahasrabudhe is a Professor of Medicine in the Division of Hematology/Oncology at the James P. Wilmot Cancer Center at the University of Rochester School of Medicine and Dentistry in Rochester, New York. Dr. Sahasrabudhe received his training at Albany Medical Center Hospital in Albany, New York and the University of North Carolina School of Medicine, Chapel Hill, North Carolina.

Dr. Sahasrabudhe is a key teaching faculty member in the Hematology/Oncology Fellowship Program. He has mentored several fellows over the last 17 years.

Dr. Sahasrabudhe's clinical research interest is in urologic malignancies. He also sees patients with melanomas and sarcomas.

Dr. Sahasrabudhe is a member of many national professional organizations including the American College of Physicians, the American Association for Cancer Research, and the American Society of Clinical Oncology.

Certified Specialties

Hematology - American Board of Internal Medicine

Internal Medicine - American Board of Internal Medicine

Medical Oncology - American Board of Internal Medicine

Faculty Appointments

Professor - Department of Medicine, Hematology/Oncology (SMD)

Professor - Cancer Center - Joint

Professor - Department of Urology (SMD) - Joint

Credentials

Residency & Fellowship

Fellowship, University of Rochester Medical Center. 1982 - 1986

Fellowship, Hematology & Oncology, University of North Carolina Healthcare-CRNA verifs. 1979 - 1982

Residency, Internal Medicine, Albany Medical Center Hospital. 1977 - 1979

Internship, Internal Medicine, Albany Medical Center Hospital. 1976 - 1977

Education

MD | University of Bombay, Lokmanya Tilak (India). 1974

Awards

Gitelman Award. 2009

Research

Clinical Trials

A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma

Lead Researcher: Deepak Madhao Sahasrabudhe MD

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an ...

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

Lead Researcher: Deepak Madhao Sahasrabudhe MD

This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinom...

A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)

Lead Researcher: Deepak Madhao Sahasrabudhe MD

The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) pos...

Pilot Study of Neoadjuvant Dual Checkpoint Blockade With Concurrent Radiation in Resectable Soft Tissue Sarcoma

Lead Researcher: Deepak Madhao Sahasrabudhe MD

Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma

Publications

Journal Articles

Current Trends in Chemotherapy in the Treatment of Metastatic Prostate Cancer.

Zhao J, Guercio BJ, Sahasrabudhe D

Cancers.. 2023 August 415 (15)Epub 08/04/2023.

Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1.

Khazan N, Quarato ER, Singh NA, Snyder CWA, Moore T, Miller JP, Yasui M, Teramoto Y, Goto T, Reshi S, Hong J, Zhang N, Pandey D, Srivastava P, Morell A, Kawano H, Kawano Y, Conley T, Sahasrabudhe DM, Yano N, Miyamoto H, Aljitawi O, Liesveld J, Becker MW, Calvi LM, Zhovmer AS, Tabdanov ED, Dokholyan NV, Linehan DC, Hansen JN, Gerber SA, Sharon A, Khera MK, Jurutka PW, Rochel N, Kim KK, Rowswell-Turner RB, Singh RK, Moore RG

Cancers.. 2023 June 3015 (13)Epub 06/30/2023.

Lack of hydroxyurea-associated mutagenesis in pediatric sickle cell disease patients

Environmental and Molecular Mutagenesis. 2023; 64(3): 1-9.

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.

Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B,

The New England journal of medicine.. 2022 March 24386 (12):1132-1142. Epub 02/17/2022.

TRAIL-coated leukocytes to kill circulating tumor cells in the flowing blood from prostate cancer patients.

Ortiz-Otero N, Marshall JR, Glenn A, Matloubieh J, Joseph J, Sahasrabudhe DM, Messing EM, King MR

BMC cancer.. 2021 August 621 (1):898. Epub 08/06/2021.

COVID-19 mRNA vaccine-related adenopathy mimicking metastatic melanoma.

Prieto PA, Mannava K, Sahasrabudhe DM

The Lancet. Oncology.. 2021 June 22 (6):e281. Epub 1900 01 01.

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.

Chou FJ, Lin C, Tian H, Lin W, You B, Lu J, Sahasrabudhe D, Huang CP, Yang V, Yeh S, Niu Y, Chang C

Cell death & disease.. 2020 November 211 (11):942. Epub 11/02/2020.

Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells.

Lin C, Chou FJ, Lu J, Lin W, Truong M, Tian H, Sun Y, Luo J, Yang R, Niu Y, Nadal R, Antonarakis ES, Cordon-Cardo C, Sahasrabudhe D, Huang CP, Yeh S, Li G, Chang C

Aging.. 2020 September 1012 Epub 09/10/2020.

Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors.

Kerns SL, Fung C, Fossa SD, Dinh PC, Monahan P, Sesso HD, Frisina RD, Feldman DR, Hamilton RJ, Vaughn D, Martin N, Huddart R, Kollmannsberger C, Sahasrabudhe D, Ardeshir-Rouhani-Fard S, Einhorn L, Travis LB

JNCI cancer spectrum.. 2020 August 4 (4):pkaa022. Epub 03/20/2020.

The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020?

Lemke E, Sahasrabudhe D, Guancial E, Bylow K, Johnson S, Messing E, Kilari D

Clinical genitourinary cancer.. 2020 January 27 Epub 01/27/2020.

Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer.

Kohli M, Oberg AL, Mahoney DW, Riska SM, Sherwood R, Zhang Y, Zenka RM, Sahasrabudhe D, Qin R, Zhang S

Clinical genitourinary cancer.. 2019 August 17 (4):248-253.e7. Epub 03/15/2019.

Estrogen receptor ? promotes bladder cancer growth and invasion via alteration of miR-92a/DAB2IP signals.

Ou Z, Wang Y, Chen J, Tao L, Zuo L, Sahasrabudhe D, Joseph J, Wang L, Yeh S

Experimental & molecular medicine.. 2018 November 2050 (11):152. Epub 11/20/2018.

A Festschrift in Honor of Edward M. Messing, MD, FACS.

Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Mohler J, Theodorescu D, Lee YF, Okunieff P, McConkey D, Rashid H, Chang C, Fradet Y, Guru K, Kukreja J, Sufrin G, Lotan Y, Bailey H, Noyes K, Schwartz S, Rideout K, Bratslavsky G, Campbell SC, Derweesh I, Abrahamsson PA, Soloway M, Gomella L, Golijanin D, Svatek R, Frye T, Lerner S, Palapattu G, Wilding G, Droller M, Trump D

Bladder cancer.. 2018 October 34 (Suppl 1):S1-S43. Epub 10/03/2018.

Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature.

Dineen M, Hansen E, Guancial E, Sievert L, Sahasrabudhe D

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.. 2018 June 24 (4):314-318. Epub 03/29/2017.

Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2018 May 2036 (15):1505-1512. Epub 04/04/2018.

Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.

Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM

JAMA.. 2018 May 8319 (18):1880-1888. Epub 1900 01 01.

TGF? Superfamily Members Mediate Androgen Deprivation Therapy-Induced Obese Frailty in Male Mice.

Pan C, Singh S, Sahasrabudhe DM, Chakkalakal JV, Krolewski JJ, Nastiuk KL

Endocrinology.. 2016 November 157 (11):4461-4472. Epub 09/09/2016.

Targeted Therapy Based on Tumor Genomic Analyses in Metastatic Urachal Carcinoma.

Loh KP, Mondo E, Hansen EA, Sievert L, Fung C, Sahasrabudhe DM, Guancial E

Clinical genitourinary cancer.. 2016 August 14 (4):e449-52. Epub 03/24/2016.

A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome.

Hansen E, Sahasrabudhe D, Sievert L

Cancer immunology, immunotherapy : CII.. 2016 June 65 (6):765-7. Epub 04/11/2016.

Reply to S. Alanee et al.

Fung C, Fossa SD, Milano MT, Sahasrabudhe DM, Peterson DR, Travis LB

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 April 1034 (11):1285-6. Epub 02/08/2016.

Ipilimumab-Induced Neutropenia in Melanoma.

Ban-Hoefen M, Burack R, Sievert L, Sahasrabudhe D

Journal of investigative medicine high impact case reports.. 2016 4 (3):2324709616661835. Epub 08/09/2016.

Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study.

Fung C, Fossa SD, Milano MT, Sahasrabudhe DM, Peterson DR, Travis LB

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015 October 133 (28):3105-15. Epub 08/03/2015.

Bladder cancer in the elderly patient: challenges and solutions.

Guancial EA, Roussel B, Bergsma DP, Bylund KC, Sahasrabudhe D, Messing E, Mohile SG, Fung C

Clinical interventions in aging.. 2015 10 :939-49. Epub 06/10/2015.

Impact of bladder cancer on health related quality of life in 1,476 older Americans: a cross-sectional study.

Fung C, Pandya C, Guancial E, Noyes K, Sahasrabudhe DM, Messing EM, Mohile SG

The Journal of urology.. 2014 September 192 (3):690-5. Epub 04/01/2014.

A case series of transformation of teratoma to primitive neuroectodermal tumor: evolving management of a rare malignancy.

Dunne RF, Sahasrabudhe DM, Messing EM, Jean-Gilles J, Fung C

Rare tumors.. 2014 January 236 (1):5268. Epub 03/18/2014.

An observational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer.

Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M

Journal of men's health.. 2012 September 19 (3):182-189. Epub 1900 01 01.

Germline predictors of androgen deprivation therapy response in advanced prostate cancer.

Kohli M, Riska SM, Mahoney DW, Chai HS, Hillman DW, Rider DN, Costello BA, Qin R, Lamba J, Sahasrabudhe DM, Cerhan JR

Mayo Clinic proceedings.. 2012 March 87 (3):240-6. Epub 1900 01 01.

Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival.

Dhakal S, Corbin KS, Milano MT, Philip A, Sahasrabudhe D, Jones C, Constine LS

International journal of radiation oncology, biology, physics.. 2012 February 182 (2):940-5. Epub 01/27/2011.

Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder.

Scosyrev E, Messing EM, van Wijngaarden E, Peterson DR, Sahasrabudhe D, Golijanin D, Fisher SG

Cancer.. 2012 January 1118 (1):72-81. Epub 06/30/2011.

Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer.

Kohli M, Rothberg PG, Feng C, Messing E, Joseph J, Rao SS, Hendershot A, Sahsrabudhe D

Cancer biomarkers : section A of Disease markers.. 2010 7 (2):101-8. Epub 1900 01 01.

Five tumors over six years in eighth decade of life.

Corbin K, Fisher S, Sahasrabudhe D, Pandya K, Brasacchio R, Constine LS

Cancer investigation.. 2008 July 26 (6):634-7. Epub 1900 01 01.

Soft tissue sarcoma in the setting of chronic cutaneous graft versus host disease after allogenic bone marrow transplantation.

Bylund KC, Giampoli E, Singh D, Doerr T, Sahasrabudhe D, Liesveld J, Constine LS

Cancer investigation.. 2008 July 26 (6):638-41. Epub 1900 01 01.

Efficacy and safety of docetaxel in the elderly

Mohile SG; Berenji F; Sahasrabudhe D; Morrow G; Petrylak D.

Aging Health. 2008; 4(2).

In vitro generation of tumor specific T cells that recognize a shared antigen of AML: molecular characterization of TCR genes.

Coppage M, Belanger T, Zauderer M, Sahasrabudhe D

Leukemia research.. 2007 February 31 (2):195-202. Epub 06/05/2006.

C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer.

Evans EE, Henn AD, Jonason A, Paris MJ, Schiffhauer LM, Borrello MA, Smith ES, Sahasrabudhe DM, Zauderer M

Molecular cancer therapeutics.. 2006 November 5 (11):2919-30. Epub 1900 01 01.

Individualized strategy for dosing luteinizing hormone-releasing hormone agonists for androgen-independent prostate cancer: identification of outcomes and costs.

Wagmiller JA, Griggs JJ, Dick AW, Sahasrabudhe DM

Journal of oncology practice. 2006 March 2 (2):57-66. Epub 1900 01 01.

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.

Rosenberg JE, von der Maase H, Seigne JD, Mardiak J, Vaughn DJ, Moore M, Sahasrabudhe D, Palmer PA, Perez-Ruixo JJ, Small EJ

Cancer.. 2005 May 15103 (10):2035-41. Epub 1900 01 01.

The influence of host response on colorectal cancer prognosis.

Shunyakov L, Ryan CK, Sahasrabudhe DM, Khorana AA

Clinical colorectal cancer.. 2004 May 4 (1):38-45. Epub 1900 01 01.

Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer.

Pandya KJ, Thummala AR, Griggs JJ, Rosenblatt JD, Sahasrabudhe DM, Guttuso TJ, Morrow GR, Roscoe JA

Breast cancer research and treatment.. 2004 January 83 (1):87-9. Epub 1900 01 01.

A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma.

Khorana AA, Rosenblatt JD, Sahasrabudhe DM, Evans T, Ladrigan M, Marquis D, Rosell K, Whiteside T, Phillippe S, Acres B, Slos P, Squiban P, Ross M, Kendra K

Cancer gene therapy.. 2003 April 10 (4):251-9. Epub 1900 01 01.

Lethality-based selection of recombinant genes in mammalian cells: application to identifying tumor antigens.

Smith ES, Mandokhot A, Evans EE, Mueller L, Borrello MA, Sahasrabudhe DM, Zauderer M

Nature medicine.. 2001 August 7 (8):967-72. Epub 1900 01 01.

CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab.

Ifthikharuddin JJ, Mieles LA, Rosenblatt JD, Ryan CK, Sahasrabudhe DM

American journal of hematology.. 2000 October 65 (2):171-3. Epub 1900 01 01.

Active specific immunotherapy for metastatic colorectal carcinoma: phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha.

Woodlock TJ, Sahasrabudhe DM, Marquis DM, Greene D, Pandya KJ, McCune CS

Journal of immunotherapy.. 1999 May 22 (3):251-9. Epub 1900 01 01.

Medical oncology and geriatric medicine: is it time for fellowship integration?

Bennett JM, Sahasrabudhe DM, Hall WJ

Cancer.. 1997 October 180 (7):1351-3. Epub 1900 01 01.

Effect of murine interferon alpha/beta on tumour-induced suppressor function.

Sahasrabudhe DM, Dusel JC

Cancer immunology, immunotherapy : CII.. 1994 December 39 (6):360-6. Epub 1900 01 01.

Shared T cell-defined antigens on independently derived tumors.

Sahasrabudhe DM, Burstyn D, Dusel JC, Hibner BL, Collins JL, Zauderer M

The Journal of immunology : official journal of the American Association of Immunologists.. 1993 December 1151 (11):6302-10. Epub 1900 01 01.

Paraneoplastic Raynaud's phenomenon.

DeCross AJ, Sahasrabudhe DM

The American journal of medicine.. 1992 May 92 (5):571-2. Epub 1900 01 01.

Suppression of delayed type hypersensitivity by desferoxamine.

Sahasrabudhe DM, Dusel J, Jedlika S

Journal of immunotherapy : official journal of the Society for Biological Therapy.. 1991 April 10 (2):112-9. Epub 1900 01 01.

Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells.

McCune CS, O'Donnell RW, Marquis DM, Sahasrabudhe DM

Cancer immunology, immunotherapy : CII.. 1990 32 (1):62-6. Epub 1900 01 01.

Inhibition of suppressor T lymphocytes by murine interferon beta.

Sahasrabudhe DM

The Journal of experimental medicine.. 1987 November 1166 (5):1573-8. Epub 1900 01 01.

Inhibition of suppressor T lymphocytes (Ts) by cimetidine.

Sahasrabudhe DM, McCune CS, O'Donnell RW, Henshaw EC

The Journal of immunology : official journal of the American Association of Immunologists.. 1987 May 1138 (9):2760-3. Epub 1900 01 01.

Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma.

Sahasrabudhe DM, deKernion JB, Pontes JE, Ryan DM, O'Donnell RW, Marquis DM, Mudholkar GS, McCune CS

Journal of biological response modifiers. 1986 December 5 (6):581-94. Epub 1900 01 01.

Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.

Capizzi RL, Yang JL, Cheng E, Bjornsson T, Sahasrabudhe D, Tan RS, Cheng YC

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 1983 December 1 (12):763-71. Epub 1900 01 01.

Decreasing M spike with increasing tumor burden in multiple myeloma.

Sahasrabudhe DM, Parker JC

Archives of internal medicine.. 1981 August 141 (9):1152-3. Epub 1900 01 01.

Books

Clinical Oncology, 8th Edition (2001)

Chapter: Soft Tissue Sarcoma

Authors: Spiro, IJ; Suit, HD; Rosier, RN; Sahasrabudhe, DM

Publisher: W.B. Saunders Company, Harcourt Brace Jovanovich Inc, Philadelphia PA 2001

Clinical Oncology, 8th Edition (2001)

Chapter: Bone Tumors

Authors: Rosier, RN; O'Keefe, RJ; Sahasrabudhe, DM

Publisher: W.B. Saunders Company, Harcourt Brace Jovanovich, Inc, Philadelphia PA 2001

Ratings & Reviews

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.